Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739510 | 1.00 | MAPK1 (0.37) | MAPK1TSHRSMN1; SMN2FABP4MAPT | |
| SCHEMBL10580640 | 0.81 | ALDH1A1 (0.41) | MAPK1TSHRSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL29739713 | 0.80 | PARP1 (0.51) | MAPTALDH1A1L3MBTL1VCAM1MEN1 | |
| SCHEMBL6634968 | 0.80 | PARP1 (0.51) | MAPTALDH1A1L3MBTL1VCAM1MEN1 | |
| SCHEMBL15084266 | 0.80 | GPR35 (0.46) | MAPK1TSHRSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL27087800 | 0.78 | VCAM1 (0.36) | MAPTALDH1A1L3MBTL1VCAM1LMNA | |
| SCHEMBL4176261 | 0.78 | MAPT (0.49) | MAPK1TSHRSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31276651 | 0.78 | MAPT (0.49) | MAPK1TSHRSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL30329748 | 0.76 | GPR35 (0.37) | MAPK1TSHRFABP4MAPTALDH1A1 | |
| SCHEMBL31009404 | 0.74 | MAPT (0.35) | MAPK1TSHRSMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| EP-1979358-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
| EP-0620809-B1 | $g(a)-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1997-03-05 | — | — | EP | disclosed |
| CN-1033451-C | Alpha-substituted benzenemethanamine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1996-12-04 | — | — | CN | disclosed |
| US-5480912-A | Method of treating HIV-1 with α-substituted benzenemethanamine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 1996-01-02 | — | — | US | disclosed |
| US-5407961-A | Useful for treating HIV-1 virus | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-04-18 | — | — | US | disclosed |
| EP-0620809-A1 | -g(a)-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES. | JANSSEN PHARMACEUTICA NV (BE) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993013052-A1 | α-SUBSTITUTED BENZENEMETHANAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-07-08 | — | — | WO | disclosed |
| CN-1073936-A | The benzenemethanamine derivatives of alpha-substitution | JANSSEN PHARMACEUTICA NV (BE) | 1993-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018128-A1 | Compounds | CNR2, CNR1, TRPV1 | MAPK1 2953/4885TSHR 2932/4885SMN1; SMN2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.